MOJ
eISSN: 2373-4442
Submit manuscript...
Mini Review Special Issue Lymphology & Phlebology
Autoimmune diseases: the new frontiers
Sabreena Safuan, Hisham Atan Edinur
Received: January 01, 1971 | Published: November 26, 2018
Citation: Safuan S, Edinur HA. Autoimmune diseases: the new frontiers. MOJ Immunol. 2018;6(6):257-262. DOI: 10.15406/moji.2018.06.00239
Abstract
Immunosuppressive drugs have long been used in the treatment of autoimmune diseases (AD). These drugs such as corticosteroids, methotrexate and cyclophosphamide cause the suppression of the immune system particularly on the T cell activation and inhibition of inflammatory cytokines production. However, patients prescribed with these drugs suffer from reduced immunity. They have increased susceptibility to serious infections and risk of malignancies. Therefore, more specific approaches against AD were developed to reduce the negative effects resulting from the blanket immunosuppression of AD-related drugs. These approaches; antigen based immunotherapy, checkpoint-based immunotherapy, targeted inflammatory cytokines and stem cell therapy, although not refined has shown great promises in animal models and were at various stages of clinical trials.
Keywords: Autoimmune diseases, Antigen-based immunotherapy, Checkpoint-based immunotherapy, Targeted inflammatory cytokines, Stem cell therapy, Drug administration, Cluster of differentiation, Cytotoxic T lymphocyte, Immune reactivity, Immune system, Immunosuppressive, Drug inhibits, Rheumatoid arthritis
©2018 Safuan, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.
Citations
Media Partner & Supporters
